Ito Toshinori, Shimada Kazunori, Gang Miao, Uchikoshi Fumihiro, Tori Masayuki, Komoda Hiroshi, Fumimoto Yuichi, Ohmori Ken, Kawamoto Koichi, Tanemura Masahiro, Nozawa Masumi
Department of Complementary and Alternative Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
Microsurgery. 2007;27(4):305-11. doi: 10.1002/micr.20361.
Pancreas transplantation (PTx) is the only therapy that can cure type 1 diabetes mellitus. With the recent advance of surgical procedures and immunosuppression, the outcome of PTx has become better than it used to be before, but some problems still remain. It is rather difficult to induce tolerance and to reverse rejection once it occurred because pancreas graft itself has a strong immunogenicity. Another important issue is regarding the recurrence of autoimmune disease in the pancreatic graft, therefore, some animal models are necessary to delineate and regulate those immune responses specific for PTx. Recently, PTx is also clinically applicable for type 2 diabetic patients with end-stage renal disease. It has been shown that insulin resistance was improved by PTx in type 2 diabetic recipients. In the current study, we have introduced some useful type 1 and type 2 diabetic models mainly based on our experimental experiences.
胰腺移植(PTx)是唯一能够治愈1型糖尿病的疗法。随着外科手术和免疫抑制技术的最新进展,胰腺移植的结果已比过去有所改善,但仍存在一些问题。由于胰腺移植物本身具有很强的免疫原性,诱导耐受以及一旦发生排斥反应后逆转排斥反应都相当困难。另一个重要问题是胰腺移植物中自身免疫性疾病的复发,因此,需要一些动物模型来描述和调节那些针对胰腺移植的特异性免疫反应。最近,胰腺移植在临床上也适用于终末期肾病的2型糖尿病患者。研究表明,胰腺移植可改善2型糖尿病受者的胰岛素抵抗。在本研究中,我们主要基于我们的实验经验引入了一些有用的1型和2型糖尿病模型。